Abraxis Bioscience, LLC

Nantbio, Inc.

Nantbioscience, Inc.

Nant Holdingsip, LLC

American Bioscience, Inc.

Nantomics, LLC

Vivorx Pharmaceuticals, Inc.

Clinical Micro Sensors, Inc.

California Capital Equity, LLC

Chunlin Tao

Neil P Desai

Patrick Soon-Shiong

Qinwei Wang

David G Ho

Paul Weingarten

Laxman Nallan

Tulay Polat

Andrew Yang

Shlomo Magdassi

Vuong Trieu

Xiaowen Sun

Zhiwen Yao

Leslie Louie

Cheng Zhi Yu

Forrest Arp

Shahrooz Rabizadeh

Sherry Ci

Chengzhi Yu

Anna B Juncker-Jensen

Sharif Asad

Hongna Han

Lukasz Koroniak

Kayvan R Niazi

Stephen Charles Benz

Changjun Yu

Paul A Sandford

Oleksandr V Buzko

Justin Golovato

Christopher W Szeto

David T Ho

Heather McFarlane

Tapas De

Tianli Zheng

Cheng-Zhi Yu

Sherry Xiaopei Ci

Heather Mcfarlane

David Ho

Niazi Kayvan

Anna Juncker-Jensen

The present inventive subject matter provides apparatus, systems, and methods in which a diagnostic test is identified, where the diagnostic test is for determining whether a particular treatment is effective for a particular patient based on one or more characteristics of a patient's cells. When a treatment is developed with the potential to treat one or more diseases, the drug can have different effects on different cell lines related to the diseases. A machine learning system is programmed to infer a measurable cell characteristic, out of many different measurable cell characteristics, that has a desirable correlation with the sensitivity data of different cell lines to a treatment. The machine learning system is programmed to then determine, based on the correlation, a threshold level of the cell characteristic the patient should exhibit in order to recommend administering the treatment.

Pathway analysis for identification of diagnostic tests

The present invention relates to the use of substituted pyrazole derivatives to modulate tropomyosin-related kinase (Trk) family protein kinase, and the use of the substituted pyrazole derivatives for the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.

Trk inhibition

The present invention provides antitumor agents comprising substituted pyrimidine derivatives and pharmaceutically-acceptable formulations thereof, methods for making novel compounds and methods for using the compounds. The compounds and compositions in accordance with the invention have utility in treatment of a variety of diseases and have kinase inhibitory activities.

Pyrimidine derivatives as kinase inhibitors and their therapeutical applications

The present invention relates to the use of substituted pyrimidine derivatives to modulate tropomyosin-related kinase (Trk) family protein kinase, and the use of the substituted pyrimidine derivatives for the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA. The present invention also provides compounds of the formula: as defined herein.

Compounds and compositions are presented that inhibit K-ras, and especially mutant K-ras. Certain compounds preferentially or even selectively inhibit specific forms of mutant K-Ras, and particularly the G12D mutant form.

Compositions and methods of targeting mutant K-RAS

Pharmaceutical compounds, compositions, and methods are presented in which various heterocyclic thiosemicarbazone derivatives are prepared. Contemplated compounds will be suitable to inhibit or reduce cellular growth or proliferation and are thus beneficial in the manufacture of drugs to treat neoplastic diseases.

Heterocyclic thiosemicarbazone derivatives and their therapeutical applications

Compounds and compositions are presented that inhibit K-Ras, and especially mutant K-Ras. Certain compounds preferentially or even selectively inhibit specific forms of mutant K-Ras, and particularly the G12D mutant form.

Compositions and methods of targeting mutant K-ras

The present invention relates generally to the use of compounds to treat a variety of disorders, diseases and pathologic conditions and more specifically to the use of substituted indol-5-ol derivatives to modulate protein kinases and for treating protein kinase-mediated diseases.

Substituted indol-5-ol derivatives and their therapeutic applications

The invention relates generally to the creation and use of cyclic sulfonamide containing derivatives to inhibit the hedgehog signaling pathway and to the use of those compounds for the treatment of hyperproliferative diseases and angiogenesis mediated diseases.

Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway

Substituted indol-5-ol derivatives and their therapeutical applications

The invention provides triazine compounds and methods of their use to modulate protein kinases and to treat diseases mediated by said protein kinases.

Benzyl substituted triazine derivatives and their therapeutical applications

The invention provides isoquinoline, quinoline, and quinazoline derivatives to treat a variety of disorders, diseases and pathologic conditions, and more specifically to the use of isoquinoline, quinoline, and quinazoline derivatives to inhibit the hedgehog signaling pathway and to the use of those compounds to the treatment of hyperproliferative diseases and pathologic angiogenesis.

Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling

Growing community of inventors

Newport Coast, CA, United States of America

Chunlin Tao